KURA ONCOLOGY, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
KURA ONCOLOGY, INC. (KURA) had Debt Securities, Available-for-sale, Unrealized Loss Position of $406.30 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $406.30M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $406.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $22.50M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $52.20M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $406.30M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $406.90M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $22.50M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $52.20M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $247.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $162.90M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $10.00M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.90M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $416.70M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $461.40M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $155.20M 10-K · filed 2025-02-28 |
| 2023-09-30 | $404.30M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $387.40M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $227.70M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $290.00M 10-K · filed 2024-02-27 |
| 2022-09-30 | $299.10M 10-Q · filed 2022-11-03 |
| 2021-12-31 | $373.90M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |